

BioVendor new products

July, 2017

Dear customer, we would like to introduce our new products and hope you will find them interesting. Below is a list of events, in which we plan to participate in 2017:

69th AACC Scientific Annual Meeting & Clinical Lab Expo (30 \ 07 \ 2017 - 03 \ 07 \ 2017 - San Diego)

MEDICA 2017 (13 \ 11 \ 2017 - 16 \ 11 \ 2017 - Düsseldorf)

IMMUNOASSAYS

NEW IMMUNOASSAYS


CAT. NO.		NAME		IVD/RUO	ASSAY FORMAT
RD191360200R	Human	Cyclophilin B ELISA	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody
RD191357200R	Human	DsbA-L ELISA	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody
RA19016R	Porcine	IFN-alpha 1 ELISA	ELISA	RUO	Sandwich ELISA, HRP-labelled antibody
RA19017R	Porcine	IFN-gamma 1 ELISA	ELISA	RUO	Sandwich ELISA, HRP-labelled antibody
RD191518200R	Human	IL-1RACP / IL-1R3 ELISA	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody
RA19019R	Porcine	Interleukin-6 ELISA	ELISA	RUO	Sandwich ELISA, HRP-labelled antibody
RA19020R	Porcine	Interleukin-10 ELISA	ELISA	RUO	Sandwich ELISA, HRP-labelled antibody
RD191246200R	Human	Intestinal FABP (FABP2) ELISA	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody
RD191473200R	Human	PCSK9 ELISA	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody
RA19018R	Porcine	TNF-alpha ELISA	ELISA	RUO	Sandwich ELISA, HRP-labelled antibody
RAF145R	Human	TNF-alpha ELISA, High Sensitivity	ELISA	RUO	Sandwich ELISA, Biotin-labelled antibody

» FEATURED PRODUCT: HUMAN PCSK9 ELISA

PCSK9 protein plays a **major regulatory role in cholesterol homeostasis**, mainly by reducing LDL-Receptor levels on the plasma membrane. Reduced LDLR levels result in decreased metabolism of LDL-particles, which could lead to **hypercholesterolemia**.


This activity made PCSK9 a novel **target in cholesterol lowering therapy**. The PCSK9 inhibitors (PSK9i) are a **newer class of injectable drugs** that have been shown to **dramatically lower LDL cholesterol** levels, by up to 60% **when combined with a statin**. PCSK9 inhibitors are monoclonal antibodies (MAbs), a type of biologic drug.

PCSK9 has a key impact not only on circulating LDL-Cholesterol level but also on cardiovascular risk and atherosclerotic process. The determination of PCSK9 levels is obviously of great diagnostic as well as treatment monitoring importance.



APPLICATIONS:

- Atherosclerosis
- Cardiovascular disease
- Lipid metabolism
- Diabetology



[RD191473200R PCSK9 Human ELISA](#)

RELATED PRODUCTS

[RD172473100 Proprotein Convertase Subtilisin/Kexin Type 9 Human HEK293](#)

RECOMBINANT PROTEINS

NEW RECOMBINANT PROTEINS

CAT. NO.		NAME	SIZE	SOURCE
RD172565100	Human	Argonaute-2	0.1 mg	<i>E. coli</i>
RD172522100	Human	Fibrinogen-Like Protein 1	0.1 mg	<i>E. coli</i>
RD172123100	Human	Renalase	0.1 mg	<i>E. coli</i>
RD172148100-E.coli	Human	TNFSF12	0.1 mg	<i>E. coli</i>
RD172125100	Human	Xylosyltransferase 2	0.1 mg	HEK293
RD172125025	Human	Xylosyltransferase 2	0.025 mg	HEK293


» FEATURED PRODUCT: HUMAN ARGONAUTE-2

Argonaute-2 (AGO2) one of the Argonaute-like proteins is **involved in RNA interference (RNAi) and microRNA (miRNA) pathways**. It is a component of the RNA-induced silencing complex (RISC) that functions in RNA-mediated gene silencing (RNAi). Argonaute-2 is the catalytic engine that drives mRNA cleavage in the RNAi pathway. It is also the primary AGO variant involved in modulating expression of progesterone receptor by antigenic RNAs. AGO1 and AGO2 reside in three complexes with distinct Dicer and RNA-induced silencing complex activities.

Argonaute-2 proteins perfectly meets and complements the current BioVendor high-priority project: miREIA - miRNA Enzyme Immunoassay

BioVendor produces recombinant Human Argonaute-2 in *E. coli*. The protein contains 869 AA. MW: 98.4 kDa (calculated). UniProtKB acc.no. Q9UKV8 (Met1-Ala859). N-terminal His-tag (10 extra AA). Protein identity confirmed by LC-MS/MS. Endotoxin < 1.0 EU/μg.

[RD172565100 Argonaute-2 Human *E. coli*](#)



NEW ANTIBODIES

CAT. NO.		PRODUCT	REACTIVE SP.	APPLICATIONS	SIZE
RD1820741003F9-01	Anti-Human	Cathepsin K, Clone: 3F9	Mouse Monoclonal Antibody	Western blotting, ELISA	0.1 mg
RD181009220-01	Anti-Human	Cystatin C	Rabbit Polyclonal Antibody	Western blotting, ELISA	0.1 mg

» FEATURED PRODUCTS: ANTI-HUMAN CATHEPSIN K, MOUSE MAB, CLONE: 3F9

An innovated version of well established and **highly popular with customers** mouse MAb anti-human Cathepsin K, **clone 3F9** is newly **produced *in vitro*** and isolated from cell culture supernatant.

Cathepsin K is closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Prostate cancer-expressed cat K may contribute to the invasive potential of CaP, while increased expression in bone metastases is consistent with a role in matrix degradation. Studies with breast cancer revealed similar results. Cathepsin K can also be considered a novel marker of obesity and a target for the inhibition of adipose mass growth.

[RD1820741003F9-01](#) Cathepsin K Human, Mouse Monoclonal Antibody, Clone: 3F9

RELATED PRODUCTS

[RD1820741003F9](#) Cathepsin K Human, Mouse Monoclonal Antibody, Clone: 3F9

[RD1820741004B9](#) Procathepsin K Human, Mouse Monoclonal Antibody, Clone: 4B

[RD181074100](#) Procathepsin K Human, Rabbit Polyclonal Antibody